AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Managing Hidradenitis Suppurativa in Diverse Populations: Strategies and Challenges

Description

The presentation discusses managing Hidradenitis Suppurativa (HS) in diverse populations, focusing on challenges and strategies, especially for ethnic minorities who are disproportionately affected. Despite advances in treatment, patients face barriers in access to care and participation in clinical trials. The speaker highlights the need for early diagnosis and a combination of medical and surgical treatments, as HS is both a surgical and medical disease. Emphasis is placed on the complexities of HS, which involves immune response, inflammation, and bacterial factors. The discussion includes statistics showcasing the prevalence of HS among Black Americans and women, the importance of addressing disparities, and the necessity of adapting care to meet diverse patient needs. The treatment protocols involve various options ranging from antibiotics to surgical interventions. It is noted that newer biologic therapies show promise but still require careful monitoring and often face accessibility issues. The presentation concludes by encouraging advocacy for better patient representation in clinical trials and continued efforts to improve awareness and support for HS patients across various ethnic backgrounds.

View more

Conclusions

  • Hidradenitis suppurativa (HS) is a complex disease predominantly affecting individuals with darker skin tones, showing significant racial disparities in prevalence and access to care.
  • Patients with HS often experience a range of comorbid conditions including depression, anxiety, and metabolic syndrome, which complicate their treatment.
  • Current treatments for HS, while improving, remain limited, and the integration of both medical and surgical therapies is essential for effective patient management.
  • Surgical intervention plays a critical role in treatment, particularly in advanced stages of HS, where sinuses and tunnels require surgical management to prevent disease progression.
  • Biologics like adalimumab and infliximab have shown efficacy in treating HS, but the representation of diverse ethnic populations in clinical trials remains insufficient.
  • Early intervention in HS is vital to prevent disease progression, highlighting the need for increased awareness and better diagnostic criteria among healthcare providers.
  • The implementation of comprehensive wound care and patient education are critical components of effective HS management, enhancing healing and quality of life for patients.
  • Patient advocacy and support services significantly impact the management of HS, as they address the psychosocial aspects of living with this chronic condition.
  • 1. Wolk et al. Br J Dermatol. 2020;183:999-1010.
  • 2. Sabat et al. Nat Rev Dis Primers. 2020;6:18.
  • 3. Navrazhina et al. J Allergy Clin Immunol. 2020;145:412-415.
  • 4. Garg A, Kirby JS, Lavian J, Lin G, Strunk A. JAMA Dermatol. 2017;153(1):87-90.
  • 5. Serrano L, Ulschmid C, Szabo A, Roth G, Sokumbi O. J Drugs Dermatol. 2023;22(7):692-693.
  • 6. Ulschmid C, Serrano L, Wu R, Roth GM, Sokumbi O. Int J Dermatol. 2023;62(5):657-663.
  • 7. Alikhan S, et al. JAAD 2019;81:91-101.DOI:10.1016/j.jaad.2019.02.068.
  • 8. Narla et al. Br J Dermatol. 2021;184:1004-13.
  • 9. Riis PT et al. JAAD 2016;74(1):10-18.
  • 10. Kimball AB, et al. N Engl J Med. 2016;375(5):422-34.